A citation-based method for searching scientific literature

Haroon Jakher, Tara I Chang, Marilyn Tan, Kenneth W Mahaffey.  2019
Times Cited: 9







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
951
22

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N. Engl. J. Med. 2008
22

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N. Engl. J. Med. 2017
22

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
22

Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Lawrence Blonde, Kaj Stenlöf, Albert Fung, John Xie, William Canovatchel, Gary Meininger. Postgrad Med 2016
35
22

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N. Engl. J. Med. 2019
701
22


Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.
Norio Akuta, Yusuke Kawamura, Chizuru Watanabe, Akihiro Nishimura, Minoru Okubo, Yasumichi Mori, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi,[...].  2019
25
11

Hepatocellular carcinoma.
Alejandro Forner, María Reig, Jordi Bruix. Lancet 2018
928
11

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Paul Angulo, David E Kleiner, Sanne Dam-Larsen, Leon A Adams, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Jill C Keach, Heather D Lafferty, Alisha Stahler,[...]. Gastroenterology 2015
880
11

Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.
Vadivel Ganapathy, Muthusamy Thangaraju, Puttur D Prasad. Pharmacol. Ther. 2009
390
11

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
Judith Ertle, Alexander Dechêne, Jan-Peter Sowa, Volker Penndorf, Kerstin Herzer, Gernot Kaiser, Jörg F Schlaak, Guido Gerken, Wing-Kin Syn, Ali Canbay. Int. J. Cancer 2011
249
11


Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Masanori Shimizu, Kunihiro Suzuki, Kanako Kato, Teruo Jojima, Toshie Iijima, Toshimitsu Murohisa, Makoto Iijima, Hidehiro Takekawa, Isao Usui, Hideyuki Hiraishi,[...]. Diabetes Obes Metab 2019
44
11

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
Christopher D Williams, Joel Stengel, Michael I Asike, Dawn M Torres, Janet Shaw, Maricela Contreras, Cristy L Landt, Stephen A Harrison. Gastroenterology 2011
11

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Qun Li, Hiroshi Tomiyama,[...]. Eur. J. Pharmacol. 2013
131
11

Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies.
Tracey G Simon, Lindsay Y King, Dawn Q Chong, Long H Nguyen, Yanan Ma, Trang VoPham, Edward L Giovannucci, Charles S Fuchs, Jeffrey A Meyerhardt, Kathleen E Corey,[...]. Hepatology 2018
28
11

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.
Yuya Seko, Taichiro Nishikawa, Atsushi Umemura, Kanji Yamaguchi, Michihisa Moriguchi, Kohichiroh Yasui, Mayumi Kimura, Hiroaki Iijima, Toshio Hashimoto, Yoshio Sumida,[...].  2018
23
11

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Damayanthi Devineni, Christopher R Curtin, David Polidori, Maria J Gutierrez, Joseph Murphy, Sarah Rusch, Paul L Rothenberg. J Clin Pharmacol 2013
123
11

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kosuke Kaji, Norihisa Nishimura, Kenichiro Seki, Shinya Sato, Soichiro Saikawa, Keisuke Nakanishi, Masanori Furukawa, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya,[...]. Int. J. Cancer 2018
25
11

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
11

Regulation of lipogenic enzyme gene expression by nutrients and hormones.
J Girard, D Perdereau, F Foufelle, C Prip-Buus, P Ferré. FASEB J. 1994
166
11


Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Teruo Jojima, Kohsuke Uchida, Kazumi Akimoto, Takanori Tomotsune, Kazunori Yanagi, Toshie Iijima, Kunihiro Suzuki, Kikuo Kasai, Yoshimasa Aso. Atherosclerosis 2017
19
11

Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.
Luca Di Tommaso, Giada Franchi, Young Nyun Park, Barbara Fiamengo, Annarita Destro, Emanuela Morenghi, Marco Montorsi, Guido Torzilli, Maurizio Tommasini, Luigi Terracciano,[...]. Hepatology 2007
206
11

Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger?
Anne P L Jensen-Urstad, Clay F Semenkovich. Biochim. Biophys. Acta 2012
112
11

Cellular aspects of alpha-fetoprotein reexpression in tumors.
G I Abelev, T L Eraiser. Semin. Cancer Biol. 1999
63
11

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Chikara Komiya, Kyoichiro Tsuchiya, Kumiko Shiba, Yasutaka Miyachi, Shunsaku Furuke, Noriko Shimazu, Shinobu Yamaguchi, Kazuo Kanno, Yoshihiro Ogawa. PLoS ONE 2016
95
11

Functional expression of sodium-glucose transporters in cancer.
Claudio Scafoglio, Bruce A Hirayama, Vladimir Kepe, Jie Liu, Chiara Ghezzi, Nagichettiar Satyamurthy, Neda A Moatamed, Jiaoti Huang, Hermann Koepsell, Jorge R Barrio,[...]. Proc. Natl. Acad. Sci. U.S.A. 2015
78
11

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Yin Liang, Kenji Arakawa, Kiichiro Ueta, Yasuaki Matsushita, Chiaki Kuriyama, Tonya Martin, Fuyong Du, Yi Liu, June Xu, Bruce Conway,[...]. PLoS ONE 2012
143
11

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya, Yasutaka Miyachi, Kentaro Mori, Noriko Shimazu, Shinobu Yamaguchi, Naomi Ogasawara, Makoto Katoh, Michiko Itoh,[...]. Sci Rep 2018
34
11

A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.
Masato Fujii, Yuichiro Shibazaki, Kyoko Wakamatsu, Yutaka Honda, Yusuke Kawauchi, Kenji Suzuki, Somasundaram Arumugam, Kenichi Watanabe, Takafumi Ichida, Hitoshi Asakura,[...]. Med Mol Morphol 2013
134
11

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.
Shirong Qiang, Yusuke Nakatsu, Yasuyuki Seno, Midori Fujishiro, Hideyuki Sakoda, Akifumi Kushiyama, Keiichi Mori, Yasuka Matsunaga, Takeshi Yamamotoya, Hideaki Kamata,[...].  2015
53
11

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.
Koki Obara, Yohei Shirakami, Akinori Maruta, Takayasu Ideta, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Takuji Tanaka, Mitsuru Seishima, Masahito Shimizu. Oncotarget 2017
17
11

Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment.
Manel Mata-Cases, Josep Franch-Nadal, Jordi Real, Mònica Gratacòs, Flora López-Simarro, Kamlesh Khunti, Dídac Mauricio. Diabetes Obes Metab 2018
21
11

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal. Lancet Diabetes Endocrinol 2016
219
11


Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain).
Irene Vinagre, Manel Mata-Cases, Eduard Hermosilla, Rosa Morros, Francesc Fina, Magdalena Rosell, Conxa Castell, Josep Franch-Nadal, Bonaventura Bolíbar, Didac Mauricio. Diabetes Care 2012
106
11


Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
146
11

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson,[...]. Lancet Diabetes Endocrinol 2017
136
11

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, Rajiv Agarwal, George L Bakris, Barry M Brenner, Scott Bull, Christopher P Cannon, David M Charytan, Dick de Zeeuw,[...]. Am. J. Nephrol. 2017
101
11

The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Matthew H Secrest, Jacob A Udell, Kristian B Filion. Trends Cardiovasc. Med. 2017
17
11


Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
11

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer,[...]. Lancet 2010
11


Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
622
11

Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Clement Lo, Tadashi Toyama, Ying Wang, Jin Lin, Yoichiro Hirakawa, Min Jun, Alan Cass, Carmel M Hawley, Helen Pilmore, Sunil V Badve,[...]. Cochrane Database Syst Rev 2018
20
11

Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
Suzanne V Arnold, Silvio E Inzucchi, Fengming Tang, Darren K McGuire, Sanjeev N Mehta, Thomas M Maddox, Abhinav Goyal, Laurence S Sperling, Daniel Einhorn, Nathan D Wong,[...]. Eur J Prev Cardiol 2017
42
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.